Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
| ▸ | GANAB | Q14697 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21146123 | 1.00 | GAA (0.35) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL21145787 | 1.00 | GAA (0.35) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL12349918 | 1.00 | GAA (0.35) | GAAGBA1MEN1CYP1A2CYP2C9 | |
| SCHEMBL24733229 | 0.87 | CHRNA7 (0.39) | GBA1HRH3CYP2D6KCNH2CHRNA7 | |
| SCHEMBL24734655 | 0.87 | CHRNA7 (0.39) | GBA1HRH3CYP2D6KCNH2CHRNA7 | |
| SCHEMBL24733191 | 0.87 | CHRNA7 (0.39) | GBA1HRH3CYP2D6KCNH2CHRNA7 | |
| SCHEMBL24789555 | 0.87 | CHRNA7 (0.39) | GBA1HRH3CYP2D6KCNH2CHRNA7 | |
| SCHEMBL24734679 | 0.86 | MAN2B1 (0.36) | HRH3CYP2D6KCNH2 | |
| SCHEMBL24789557 | 0.86 | MAN2B1 (0.36) | HRH3CYP2D6KCNH2 | |
| SCHEMBL24734677 | 0.86 | MAN2B1 (0.36) | HRH3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | GAA 1088/4885GBA1 777/4885MEN1 4740/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | GAA 1088/4885GBA1 777/4885MEN1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.